Engitix Licenses Lonza’s Technology to Advance ADC Therapies

Lonza, through one of its affiliated companies, is eligible to receive upfront, clinical, regulatory, and commercial milestone payments, plus royalties on the net sales of resulting products.

The post Engitix Licenses Lonza’s Technology to Advance ADC Therapies appeared first on GEN - Genetic Engineering and Biotechnology News.